CAMBRIDGE, Mass. — Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation radiopharmaceuticals for cancer treatment, has named Andrew Davis as its Chief Business and Strategy Officer.
Davis, who most recently served as Chief Business Officer at Dynavax Therapeutics, will join the company’s executive leadership team as it advances its lead candidate, CONV01-α, and prepares for later-stage clinical development.
“We are excited to welcome Andrew to Convergent as we look ahead to key data milestones for CONV01-α and work to bring a new therapeutic option to patients with advanced metastatic castration-resistant prostate cancer,” said Philip Kantoff, MD, CEO and co-founder of Convergent Therapeutics. “Andrew’s experience and leadership will be critical as we drive pipeline growth and prepare for late-stage clinical studies and beyond.”
Davis brings more than 20 years of experience in biopharmaceutical strategy, mergers and acquisitions, and commercial operations. Prior to Dynavax, he served as Chief Business Officer at Ironwood Pharmaceuticals and as Chief Business Development and M&A Officer at iNova Pharmaceuticals.
Earlier in his career, Davis was Head of Oncology Business Development at Merck, where he focused on partnerships to expand the company’s oncology pipeline. He also held senior roles at Bausch Health Companies, where he led major acquisitions, including Salix Pharmaceuticals, Dendreon, and Bausch + Lomb. He began his career as an analyst at McKinsey & Co., working primarily in the healthcare sector.
“I am thrilled to join Convergent at such an important and exciting time for the company. Alpha-emitting radioantibodies represent a genuinely new therapeutic paradigm with the potential to establish a new standard-of-care for patients with prostate cancer,” said Davis. “The opportunity to help shape this emerging market and forge the collaborations needed to bring this therapeutic candidate to patients is tremendously exciting. I look forward to working alongside the entire Convergent team to realize the full promise of CONV01-α and the broader potential of the company’s pipeline.”
Davis holds a bachelor’s degree in economics from Boston University and currently serves on the board of Vedanta Biosciences. He previously served on the board of UTILITY Therapeutics Ltd.
